title: Conventional monotherapy compared to a "sawtooth" treatment strategy in the radiographic progression of rheumatoid arthritis over the first eight years.
abstract: OBJECTIVE
  To describe the treatment with disease-modifying antirheumatic drugs (DMARDs) in two inception cohorts of rheumatoid arthritis (RA) patients and to compare their radiographic outcomes.
  
  
  METHODS
  A recent onset RA cohort was collected in Heinola in 1973-1975, and another in Jyväskylä in 1983-1989. The cohorts were followed up prospectively and treated with available DMARDs. The radiographic outcomes of 103 and 85 seropositive cohort patients from Heinola and Jyväskylä respectively were assigned Larsen scores (0-100) for their wrist, hand and foot radiographs in years 0, 1, 3, and 8, and compared with each other.
  
  
  RESULTS
  In this study it was seen that DMARD treatment for RA became more extensive over time. The earlier cohort patients were treated with gold sodium thiomalate, chloroquine and D-penicillamine, while 8 additional DMARDs and various DMARD combinations were used for the later cohort patients. At the 8 year visit, 23%, 33%, and 2% of the Heinola patients, and 6%, 45%, and 21% of the Jyväskylä patients respectively were being treated with chloroquine, other single DMARDs, or DMARD combinations. Destruction in the peripheral joints remained lower in the more extensively treated cohort; from 0 to 8 years the median Larsen score increased from 1 to 25.5 and from 0 to 12 (p = 0.001) for the Heinola and the Jyväskylä patients, respectively.
  
  
  CONCLUSIONS
  Our result supports a role of DMARDs in preventing joint destruction in RA in the long-term.
authors.affiliation: Department of Medicine, Jyväskylä Central Hospital, Finland. tuulikki.sokka@ksshp.fi
authors.forename: T M
authors.initials: TM
authors.lastname: Sokka
authors.forename: K
authors.initials: K
authors.lastname: Kaarela
authors.forename: T T
authors.initials: TT
authors.lastname: Möttönen
authors.forename: P J
authors.initials: PJ
authors.lastname: Hannonen
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D001310:Auranofin / Q000008:administration & dosage; D001379:Azathioprine / Q000008:administration & dosage; D002738:Chloroquine / Q000008:administration & dosage; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006052:Gold Sodium Thiomalate / Q000008:administration & dosage; D006801:Humans; D007596:Joints / Q000473:pathology; D008137:Longitudinal Studies; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010396:Penicillamine / Q000008:administration & dosage; D011446:Prospective Studies; D011859:Radiography; D012720:Severity of Illness Index; D012460:Sulfasalazine / Q000008:administration & dosage
chemical_list: D018501:Antirheumatic Agents; D006052:Gold Sodium Thiomalate; D001310:Auranofin; D012460:Sulfasalazine; D002738:Chloroquine; D010396:Penicillamine; D001379:Azathioprine; D008727:Methotrexate